



# Dr. Ishfaq Bukhari Associate Professor of Pharmacology College of Medicine, KSU

#### **OBJECTIVES**

- \* At the end of lecture, the students should:
- Discuss the etiology of tuberculosis
- Discuss the common route for transmission of the disease
- \* Discusses the out line for treatment of tuberculosis
- Discuss the drugs used in the first & second line

# OBJECTIVES (continue)


#### Regarding:

- \* The mechanism of action
- Adverse effects
- Drug interactions
- Contraindication
- Discuss tuberculosis & pregnancy
- Discuss tuberculosis & breast feeding




Mycobacterium tuberculosis, slow growing, an acid fast bacillus

❖ Robert Koch was the first to see Mycobacterium tuberculosis with his staining technique in 1882.






#### Disease information:



Each year, 1% of the global population is infected.

More than one third of the world's population has **tuberculosis**.



# YOUR COUGHS AND SNEEZES



#### SPRAY SPREADS COLDS · FLU · TUBERCULOSIS

THE RESIDENCE THERE OF Christman Saule made the Poster Posterial

#### **Tuberculosis**

**Common sites of infections** 

- \* Apical areas of lung
- \* Renal parenchyma
- Growing ends of bones

#### **Treatment Of Tuberculosis**

- \*Preventing development of drug resistance is the most important reason to use drug combination.
- \*Periods of treatment (minimum 6 months)
- \*Drugs are divided into two groups:
- 1. First line 2. Second line

# Antimycobacterial drugs

#### First line

- \*Isoniazid (INH)
- \* Rifampin
- \*Ethambutol
- \* Pyrazinamide

Given for first 8 weeks, followed by INH/RIF for 18 weeks

Streptomycin (should not be the first line choice)

# Never use a single drug therapy

- \*Isoniazid –rifampin combination administered for 9 months will cure 95-98% of cases.
- \*Addition of pyrazinamide/ethambutol for this combination for the first 2 months allows total duration to be reduced to 6 months.

#### **Isoniazid**

- \*Bacteriostatic for resting bacilli.
  - \*Bactericidal for rapidly growing bacilli.
  - \*Is effective against intracellular & extracellular bacilli

#### **Mechanism Of Action**

Inhibits the synthesis of mycobacterial

cell wall (inhibit the synthesis of mycolic acid)

#### Clinical uses

- \* Treatment of TB
- Treatment of Latent TB in patients with positive tuberculin skin test
- Prophylaxis against active TB in individuals who are in great risk.

#### Adverse effects

- \*Peripheral neuritis
  - (pin & needles sensation in the feet
- \*Optic neuritis & atrophy.
  - (Pyridoxine should be given in both cases )
- \*Hepatitis (toxic metabolites)
- Hepatitis with INH, is age dependent; it is rare in persons younger than 20 years, risk increases with age and alcohol use

# Drug Interactions of INH

- Enzyme inhibitor
- \*Slow and fast acetylators.



- \*Bactericidal
- Inhibits RNA synthesisby binding to DNA dependent RNA

polymerase enzyme.

## Site of Action (similar to INH)

- \*Intracellular bacilli
- \*Extracellular bacilli

#### Clinical uses

\*Treatment of TB

\*Prophylaxis.

#### Adverse effects

- \*Harmless red-orange discoloration of body secretions (saliva, sweat, tears ....). Tell the patient about this effect. Can permanently stain contact lenses.
- \*Hepatitis less common compared to INH
- Flu-like syndrome
- \* Hemolytic anemia

# **Drug Interactions**

- Enzyme inducer
- Clincally significant drug interactios such as warfarin, methadone will be metabolized faster

#### **Ethambutol**

\*Bacteriostatic

\*Inhibitor of mycobacterial arabinosyl transferase (alters the cell barrier) disrupts the assembly of mycobacterial cell wall.

# Site Of Action (similar to INH)

\*Intracellular & Extracellular bacilli

#### Clinical uses

\*Treatment of tuberculosis in combination with other drugs.

#### Adverse effects

Impaired visual acuity

\*red-green color blindness.

 Ethambutol is contraindicated in children under 5 years.

# Pyrazinamide

- \*Bacteriostatic
- \*Mechanism of action is unknown.

#### Site Of Action

\* Active against Intracellular Bacilli

#### Clinical uses

- \*Mycobacterial infections mainly in multidrug resistance cases.
- \*It is important in short –course (6 months) regimen.
- \*Prophylaxis of TB.

#### Adverse effects

\*Hepatotoxicity (common)

\*Hyperuricemia (gouty arthritis)

Drug fever & skin rash

# Streptomycin

- \*Bactericidal
- \*Inhibitors of protein synthesis by binding to 30 S ribosomal subunits.
- \*Active mainly on extracellular bacilli

#### Clinical uses

\*Severe, life-threating form of T.B. as meningitis, disseminated disease.



- **\*** Ototoxicity
- \*Nephrotoxicity
- \*Neuromuscular block

# Indication of 2<sup>nd</sup> line treatment

- \*Resistance to the drugs of 1st line.
- \*Failure of clinical response
- \*There is contraindication for first line drugs.
- \* Used in typical & atypical tuberculosis
- \* 2<sup>nd</sup> line drugs are more toxic than 1<sup>st</sup> line drugs

### Ethionamide

\*Inhibits the synthesis of mycolic acid

## Clinical uses

\*As a secondary line agent ,treatment of TB.

## **Adverse Effects**

Terratogenic

Poorly tolerated

Because of:

- \*Severe gastric irritation &
- \*Neurological manifestations

# Fluoroquinolones (Ciprofloxacin )

**\*Effective against multidrug- resistant tuberculosis.** 

### Rifabutin

- \* RNA inhibitor
- Cross –resistance with rifampin is complete.
- \*Enzyme inducer

### Clinical uses

\*Effective in prevention &treatment of T.B.

\*In prevention & treatment of atypical TB.

### **Adverse Effects**

**\*GIT** intolerance

\*Orange-red discoloration of body secretions.

# Aminosalicylic Acid (PAS).

\*Bacteriostatic

\*Inhibits Folic acid synthesis.

### Clinical uses

\*As a second line agent is used in the treatment of pulmonary & other forms of tuberculosis.

## Adverse effects

\*GIT upset

\* Crystalluria

# TB & Pregnancy

- Untreated TB represents a great risk to the pregnant woman & her fetus than the treatment itself.
- First line (INH, Ethmabutol and rifampicin)
   drugs are given for 9 months in normal doses
- \* Streptomycin not used

# TB & Breast Feeding

\* It is not a contraindication to receive drugs, but caution is recommended



